Browse News

Found 4,788 articles

• Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

  11/14/2018

  With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients

• Sutro Biopharma Reports Third Quarter 2018 Financial Results

  11/14/2018

  STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma

• Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma

  11/14/2018

  Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

• 

  Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardio...

  11/13/2018

  Viagra (sildenafil), Pfizer’s blockbuster drug for erectile dysfunction, is a classic example of how a drug developed for one thing can turn out to be successful for another. 

• Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018

  11/13/2018

  Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced its results for the three-month period ended September 30, 2018 and for the nine-month period end September 30, 2018.

• OncLive® to Host State of the Science Summit™ on Multiple Myeloma

  11/13/2018

  OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will present its latest State of the Science Summit™ on diagnosis, management, and treatment of multiple myeloma.

• GenomOncology announces partnership with Indiana University School of Medicine

  11/13/2018

  GenomOncology to provide clinical researchers with real-time clinical trial matching in support of IU's Grand Challenge Precision Health Initiative

• Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

  11/13/2018

  Initiation of Phase 1 Trial Planned for Early 2019

• Harpoon Therapeutics Announces Closing of $70M Series C Financing

  11/11/2018

  Proceeds to Advance Pipeline of Cancer Immunotherapies

• New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

  11/9/2018

  First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146

• The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in Funding

  11/8/2018

  LLS adds 80 new grants - $42 million globally - to its robust research portfolio

• Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

  11/8/2018

  Sharp to Bring Additional Financial Expertise to Sutro's Board

• Ligand Reports Third Quarter 2018 Financial Results

  11/8/2018

  Raises 2018 Financial Guidance

• 

  BMS’ Empliciti Garners a New FDA Indication for Multiple Myeloma

  11/7/2018

  Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.

• Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma

  11/7/2018

  Verastem, Inc. today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma

• Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting

  11/7/2018

  With New Data, Merck Now has Presented Early Clinical Data for Six Investigational Oncology Pipeline Candidates Spanning Several Pathways

• Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data

  11/7/2018

  Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.

• Halozyme Reports Third Quarter 2018 Financial Results

  11/6/2018

  ENHANZE® Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future Milestone and Royalty Payments

• U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma

  11/6/2018

  Bristol Myers Squibb Company today announced that the U.S. Food and Drug Administration approved Empliciti injection for intravenous use

• First Patient Enrolled in Investigator-Initiated Study of Tinostamustine in Glioblastoma

  11/6/2018

  Now open at The University of Texas MD Anderson Cancer Center, the open-label, non-randomized trial will investigate the safety profile, maximum tolerated dose, and efficacy of tinostamustine.